Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials
Nom du journal : Br J Cancer
Année : 2020
Volume : 122
Page de départ : 759
Page de fin : 765